AKT1 and gastrointestinal stromal tumor: Previously, our group had shown that treatment with IM in combination with the pan-AKT inhibitor MK-2206 demonstrated increased efficacy in IM-sensitive and IM-resistant GIST cell lines, as well as extended disease stabilization and improved survival in an IM-sensitive xenograft model compared to IM treatment alone [19].